[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.52.237. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
From The Medical Letter on Drugs and Therapeutics
May 12, 2015

A 4-Drug Combination (Viekira Pak) for Hepatitis C

JAMA. 2015;313(18):1857-1858. doi:10.1001/jama.2015.4562

The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype 1 infection (Table 1). Genotype 1 is responsible for 70%-80% of HCV infections in the US.

First Page Preview View Large
First page PDF preview
First page PDF preview
×